Brothers Who Made Billions on US Pharma Firm Revamp Health Bets
The Giulianis are selling Royalty Pharma stock as they invest in other health-focused firms, including a SPAC that merged with biotech business ProKidney.
This article is for subscribers only.
Germano and Giammaria Giuliani are reworking bets on the sector that put them among the world’s ultra-rich.
The brothers have started cutting their roughly $2.4 billion stake in Royalty Pharma Plc for the first time since its New York listing more than two years ago. Their investment funds have filed to sell up to almost $100 million of stock in the company, which buys pharmaceutical royalties, after offloading about $150 million — or roughly 6% of their holding — in recent months.